V K Dhingra1, A Uusaro, C L Holmes, K R Walley. 1. University of British Columbia Program of Critical Care Medicine and McDonald Research Laboratories, St. Paul's Hospital, Vancouver, Canada.
Abstract
BACKGROUND: Acute lung injury leading to a systemic inflammatory response greatly increases mortality in critically ill patients. Cardiovascular management of these patients frequently involves beta-adrenergic agonists. These agents may alter the inflammatory response. Therefore, the authors tested the hypothesis that beta-adrenergic agonists alter the pulmonary inflammatory response during acute lung injury in mice. METHODS: Five-week-old CD-1 mice received continuous infusions of 10 microg x kg(-1) x min(-1) dobutamine, 6 microg x kg(-1) x min(-1) dopexamine, or vehicle via intraperitoneal mini osmotic pumps, followed immediately by intratracheal instillation of approximately 2 microg/kg endotoxin (or phosphate-buffered saline control). Six hours later the mice were killed, and lung lavage was performed. Interleukin-6 and -10 concentrations in lung homogenates were measured using enzyme-linked immunosorbent assay. Interleukin-6 and macrophage inflammatory protein-2 mRNA was measured using reverse-transcription polymerase chain reaction. RESULTS: Interleukin-6 protein and mRNA significantly increased after intratracheal endotoxin (P < 0.001), and the fraction of neutrophils in lung lavage fluid increased in endotoxin-treated (41 +/- 25%) versus control mice (2 +/- 4%, P < 0.05). Treatment of endotoxic mice with dobutamine significantly decreased interleukin-6 protein (P < 0.05) and mRNA (P < 0.05) expression. Dopexamine had similar but less pronounced effects. Dobutamine decreased interleukin-10 expression, whereas dopexamine did not. In endotoxemic mice, both dobutamine and dopexamine decreased induction of macrophage inflammatory protein-2 mRNA (P < 0.05) and reduced the fraction of neutrophils in lung lavage fluid (P < 0.05). CONCLUSIONS: In endotoxin-induced acute lung injury, beta-adrenergic agonists can significantly decrease proinflammatory cytokine expression, decrease induction of chemokine mRNA, and decrease the resultant neutrophil infiltrate in the lung.
BACKGROUND:Acute lung injury leading to a systemic inflammatory response greatly increases mortality in critically illpatients. Cardiovascular management of these patients frequently involves beta-adrenergic agonists. These agents may alter the inflammatory response. Therefore, the authors tested the hypothesis that beta-adrenergic agonists alter the pulmonary inflammatory response during acute lung injury in mice. METHODS: Five-week-old CD-1mice received continuous infusions of 10 microg x kg(-1) x min(-1) dobutamine, 6 microg x kg(-1) x min(-1) dopexamine, or vehicle via intraperitoneal mini osmotic pumps, followed immediately by intratracheal instillation of approximately 2 microg/kg endotoxin (or phosphate-buffered saline control). Six hours later the mice were killed, and lung lavage was performed. Interleukin-6 and -10 concentrations in lung homogenates were measured using enzyme-linked immunosorbent assay. Interleukin-6 and macrophage inflammatory protein-2 mRNA was measured using reverse-transcription polymerase chain reaction. RESULTS:Interleukin-6 protein and mRNA significantly increased after intratracheal endotoxin (P < 0.001), and the fraction of neutrophils in lung lavage fluid increased in endotoxin-treated (41 +/- 25%) versus control mice (2 +/- 4%, P < 0.05). Treatment of endotoxic mice with dobutamine significantly decreased interleukin-6 protein (P < 0.05) and mRNA (P < 0.05) expression. Dopexamine had similar but less pronounced effects. Dobutamine decreased interleukin-10 expression, whereas dopexamine did not. In endotoxemic mice, both dobutamine and dopexamine decreased induction of macrophage inflammatory protein-2 mRNA (P < 0.05) and reduced the fraction of neutrophils in lung lavage fluid (P < 0.05). CONCLUSIONS: In endotoxin-induced acute lung injury, beta-adrenergic agonists can significantly decrease proinflammatory cytokine expression, decrease induction of chemokine mRNA, and decrease the resultant neutrophil infiltrate in the lung.
Authors: Markus Bosmann; Jamison J Grailer; Ketong Zhu; Michael A Matthay; J Vidya Sarma; Firas S Zetoune; Peter A Ward Journal: FASEB J Date: 2012-02-07 Impact factor: 5.191
Authors: Sanjay Manocha; Anthony C Gordon; Ebrahim Salehifar; Horacio Groshaus; Keith R Walley; James A Russell Journal: Crit Care Date: 2006-02 Impact factor: 9.097
Authors: John K McGee; Lung Chi Chen; Mitchell D Cohen; Glen R Chee; Colette M Prophete; Najwa Haykal-Coates; Shirley J Wasson; Teri L Conner; Daniel L Costa; Stephen H Gavett Journal: Environ Health Perspect Date: 2003-06 Impact factor: 9.031
Authors: Oriol Roca; Susana Gómez-Ollés; Maria-Jesús Cruz; Xavier Muñoz; Mark J D Griffiths; Joan R Masclans Journal: Crit Care Date: 2008-05-30 Impact factor: 9.097
Authors: David Van Ly; Monique De Pedro; Peter James; Lucy Morgan; Judith L Black; Janette K Burgess; Brian G G Oliver Journal: Respir Res Date: 2013-11-15